A private equity firm with offices China makes late venture and growth stage investments exclusively in the life sciences and has invested in nearly 50 companies to date. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.
The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.
The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Author: Next Phase Admin
Hot Investor Mandate: Europe-Based Family Office Invests in Devices & Digital Health Companies in High Unmet Medical Need Areas Including CNS, Ophthalmology, Chronic Diseases, Etc.
A family office based in Europe invests in healthcare and technology companies, and seeks to partner with awesome entrepreneurs who are transforming healthcare – solving big problems and creating great companies. Typical investment is $200k-1M and the firm seeks to invest globally.
The firm‘s interests include chronic eye diseases, diabetes, Parkinson’s, Alzheimer’s, AI-enabled breast cancer detection, stroke, chronic kidney disease, digital health, medical devices, telemedicine. The firm does not actively review opportunities in therapeutics at this time.
The firm partners with resourceful entrepreneurs who have proven their ability to get results.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Clinical-Stage Biopharmaceutical Company Seeks to Partner with Early-Stage Pre-Clinical to Early Clinical Stage Therapeutics in Oncology, Ophthalmology, and More
A clinical stage biopharmaceutical company with multiple offices in China and USA is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing, and is currently developing nine therapeutic antibody molecules targeting multiple indications. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.
The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.
The firm has no specific company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Healthcare-Focused Venture Fund Looks for USA-Based Companies with Strong Interest in Platform Technologies and Drug Development-Enabling Technologies
An early-stage healthcare venture fund established in 2018 with USA-based teams looks to invest in companies and teams with novel approaches in both the life sciences and Bio-IT sector.
The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Bio-IT sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow.
The firm is actively looking for companies from Seed to Series A and is focused on the US with select opportunities globally.
The firm is focused on two main investment themes:
(1) Life Sciences – The firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and immune based disease. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;
(2) Bio IT – Bio IT is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery / development (proteomics and metabolomics), and new solutions to improve the efficiency of new modalities (i.e., cell therapy manufacturing, gene therapy carries, etc.).
The firm is looking for experienced management teams with strong scientific expertise and management skills.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Keep Your Startup Out of the “Valley of Death”
Join Life Science Managing Director, Nishta Rao and First Republic Bank at 12 PM EDT to learn how to keep your startup out of the “Valley of Death” and how a solid banking partner can help and add value to the early stage. Additional speakers include:
– Richard Austin, PhD, MBA, CEO, Reglagene
– Bhawanjit Brar, PhD, Founder & CEO, Jaan Biotherapeutics
– Jessica Gibson, MBA, Co-Founder & CEO, Ariel Medicine
– Danny Talati, PharmD, MBA, Senior Vice President, Corporate Strategy, Cognesy Therapeutics
We hope you’ll join us!
https://us02web.zoom.us/j/83314503728?pwd=UVFDLzB4Qm50UlZmelRRNmRyNWJNUT09
LSN Strikes Again, with a Content Only $250 Audience Access Ticket (AAT) to RESI June
By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
During Covid, Life Science Nation (LSN) changed the partnering landscape and emphatically proved that virtual “matched” meetings could thrive and deals could get done. LSN is leading the way again with this special $250 ticket aimed at scientist-entrepreneurs and first-time fundraising CEOs. Many of these players lack a support system to help them navigate the move from academia to a commercial startup entity. In many instances, they underestimate the critical importance of sales, marketing, and business development even at an early stage, and lack a marketing budget putting conferences out of reach.
With the Audience Access Ticket, these companies gain live access to RESI’s numerous panels, workshops, and pitch sessions, allowing them to benefit from investors, industry experts and successful entrepreneurs providing insights that can help them understand what they need to make the best impression in their fundraising campaigns. In addition to the live access, users also get access to all recordings for an additional three weeks following the conference.
Dennis Ford, Founder and CEO of LSN states “Exposing the startup executives to the LSNs global network early on in the partnering process through an Audiences Access Ticket, will really flip a few switches on in their heads. They will be able to see firsthand how other entrepreneurs have successfully executed their global partnering campaigns. Seeing is believing, and early stage entrepreneurs need to observe how other entrepreneurs prepare for events like RESIs Innovator’s Pitch Challenge and hear directly from scientist-entrepreneurs and fundraising CEOs in the Tales From The Road panels. LSN has been delivering a line-up of the who’s who of capital investors and licensing partners who participate on panels aimed at providing entrepreneurs with insight as to how they fill their investment mandates for portfolio companies and how Pharma business development executives source and license technology assets for their product pipelines.”
Candice He, LSN’s VP of Business Development says “Providing access to the 16 capital investor and licensing partner panels is exactly what is needed for these first-time entrepreneurs to cross the chasm and get serious about their partnering initiatives. LSN believes that we have an invaluable content resource that we need to share that and get the early stage executives immersed in the partnering marketplace.“
RESI is unique in that its main draw is its match-based partnering platform. Most other life science conferences use content as the lead draw and partnering secondary. However that doesn’t change the fact that RESI content is also world class. Because RESI is a dedicated partnering event, its content is 100% partnering oriented, and all the panels and workshops revolve around investors and licensing partners educating entrepreneurs on how they source and evaluate, and their process of doing business with startups. Plugging into this network, even at the earliest stages, allows companies to get a head start on learning who the key players are, and can help them more easily navigate their future partnering campaigns. Learn more about each content feature of the Audience Access pass and register today for a special $250 offer!
| Digital RESI June 7-9, 2022 Agenda | |||
| Tuesday (6/7) | Wednesday (6/8) | Thursday (6/9) | |
| 10AM EDT | IPC Session #1 Therapeutics | IPC Session #4 Therapeutics | IPC Session #8 AI (Devices & Digital Health) |
| 11AM EDT | Beyond Big Pharma Partnering & Perspectives from Small and Mid-Sized Biotech |
AI vs. Life Science Which Comes First in Early-Stage Investment? |
Age-Tech Care Management Technology Improving the Lives of Older Adults |
| 12PM EDT |  Keeping Your Life Science Startup Out of the “Valley of Death” |
 Negotiating Term Sheets: What’s Best for the Company and What’s Best for You? |
 SEEDing Biomedical Innovation: Support for Small Businesses at NIH |
| 1PM EDT | Angel Investors Explaining the Process of Engagement |
Corporate VC The Changing Landscape & New Opportunities |
Impact Investors More Than Financial Returns |
| IPC Session #2 Medical Devices | IPC Session #5 Medical Devices | IPC Session #9 Therapeutics and R&D Services |
|
| 2PM EDT | The Neuroscience of Aging Aging Impact on the Nervous System |
Asia Cross-Border Building Global Partnerships |
Team, Tech, and Traction in Early-Stage AI Building Your Startup as a Triple Threat |
| 3PM EDT |  Fundraising Bootcamp |
IPC Session #4 Therapeutics | Software-Enabled Medical Devices Investing at the Intersection of Digital Health and Medtech |
| 4PM EDT | Tales from the Road: AI Innovation in Healthcare Standing Out in a Growing Field |
Tales from the Road: Age-Related Diseases Developing Prevention & Treatments |
Tales from the Road: Biotech and MedTech Innovators Entrepreneurs on Their Fundraising Journey |
| 5PM EDT | IPC Session #3 Devices & Diagnostics | IPC Session #7 AI (Devices & Digital Health) | IPC Session #10 Therapeutics |
Investors Making a Splash at RESI
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
RESI is a frequent stop along the way for many investors seeking assets in early-stage life science and healthcare. Additionally, new investors are added each week to the RESI network and attend events with an open mind, looking to source promising assets. Check out the confirmed investors for Digital RESI, June 7-9. Partnering is open and most meetings are booked in the final days leading up to the conference, so there is still time left to make important connections. Learn more and sign up today!
RESI is a frequent stop along the way for many investors seeking assets in early-stage life science and healthcare. Additionally, new investors are added each week to the RESI network and attend events with an open mind, looking to source promising assets. Check out the confirmed investors for Digital RESI, June 7-9. Partnering is open and most meetings are booked in the final days leading up to the conference, so there is still time left to make important connections. Learn more and sign up today!
Confirmed Digital RESI June 2022 Investors
